Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5508575 | 1.00 | BCAT2 (0.42) | BCAT2HCAR2ALDH1A1HPGDBCL2 | |
| SCHEMBL2160122 | 0.81 | ALDH1A1 (0.41) | BCAT2HCAR2ALDH1A1HPGDKDM4E | |
| SCHEMBL756357 | 0.81 | ALDH1A1 (0.41) | BCAT2HCAR2ALDH1A1HPGDKDM4E | |
| SCHEMBL2160129 | 0.81 | ALDH1A1 (0.41) | BCAT2HCAR2ALDH1A1HPGDKDM4E | |
| SCHEMBL28633617 | 0.79 | BCAT2 (0.35) | BCAT2HCAR2ALDH1A1 | |
| SCHEMBL28633615 | 0.79 | BCAT2 (0.35) | BCAT2HCAR2ALDH1A1 | |
| SCHEMBL503440 | 0.78 | FDPS (0.54) | ALDH1A1HPGDKDM4E | |
| SCHEMBL29417369 | 0.78 | FDPS (0.54) | ALDH1A1HPGDKDM4E | |
| SCHEMBL44077 | 0.78 | FDPS (0.54) | ALDH1A1HPGDKDM4E | |
| SCHEMBL30410840 | 0.78 | HCAR2 (0.46) | HCAR2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773877-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006014287-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | claimed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
| US-20240150405-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-05-09 | — | — | US | disclosed |
| US-11845808-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2023-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | BCAT2 75/4885HCAR2 4059/4885ALDH1A1 4766/4885 |
| US-20240150405-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | BCAT2 2022/4885HCAR2 340/4885ALDH1A1 4574/4885 |
| US-11845808-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | BCAT2 2022/4885HCAR2 340/4885ALDH1A1 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.